X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ALKEM LABORATORIES AJANTA PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 24.5 - - View Chart
P/BV x 10.1 7.4 135.5% View Chart
Dividend Yield % 0.6 0.6 102.2%  

Financials

 AJANTA PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ALKEM LABORATORIES
Mar-16
AJANTA PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7201,589 108.2%   
Low Rs1,1031,232 89.5%   
Sales per share (Unadj.) Rs194.6417.5 46.6%  
Earnings per share (Unadj.) Rs45.256.3 80.3%  
Cash flow per share (Unadj.) Rs50.364.7 77.7%  
Dividends per share (Unadj.) Rs8.0012.70 63.0%  
Dividend yield (eoy) %0.60.9 62.9%  
Book value per share (Unadj.) Rs132.0292.9 45.1%  
Shares outstanding (eoy) m88.77119.57 74.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.4 214.7%   
Avg P/E ratio x31.225.1 124.6%  
P/CF ratio (eoy) x28.121.8 128.7%  
Price / Book Value ratio x10.74.8 222.0%  
Dividend payout %17.722.6 78.4%   
Avg Mkt Cap Rs m125,299168,653 74.3%   
No. of employees `000NANA-   
Total wages/salary Rs m2,5709,171 28.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,27549,915 34.6%  
Other income Rs m1661,645 10.1%   
Total revenues Rs m17,44251,561 33.8%   
Gross profit Rs m5,8078,482 68.5%  
Depreciation Rs m4511,006 44.8%   
Interest Rs m49671 7.3%   
Profit before tax Rs m5,4748,451 64.8%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,606 90.9%   
Profit after tax Rs m4,0146,731 59.6%  
Gross profit margin %33.617.0 197.8%  
Effective tax rate %26.719.0 140.3%   
Net profit margin %23.213.5 172.3%  
BALANCE SHEET DATA
Current assets Rs m7,63927,062 28.2%   
Current liabilities Rs m2,71515,324 17.7%   
Net working cap to sales %28.523.5 121.2%  
Current ratio x2.81.8 159.3%  
Inventory Days Days4367 65.0%  
Debtors Days Days7941 190.6%  
Net fixed assets Rs m6,91412,610 54.8%   
Share capital Rs m177239 74.0%   
"Free" reserves Rs m11,44234,490 33.2%   
Net worth Rs m11,72135,027 33.5%   
Long term debt Rs m1491,212 12.3%   
Total assets Rs m14,81454,387 27.2%  
Interest coverage x112.913.6 830.3%   
Debt to equity ratio x00 36.7%  
Sales to assets ratio x1.20.9 127.1%   
Return on assets %27.413.6 201.5%  
Return on equity %34.219.2 178.2%  
Return on capital %46.524.9 187.2%  
Exports to sales %55.112.9 426.1%   
Imports to sales %6.03.1 194.6%   
Exports (fob) Rs m9,5276,461 147.5%   
Imports (cif) Rs m1,0381,540 67.4%   
Fx inflow Rs m10,4226,563 158.8%   
Fx outflow Rs m1,6783,012 55.7%   
Net fx Rs m8,7443,552 246.2%   
CASH FLOW
From Operations Rs m3,2647,259 45.0%  
From Investments Rs m-2,0931,864 -112.3%  
From Financial Activity Rs m-1,186-9,273 12.8%  
Net Cashflow Rs m-15-150 9.9%  

Share Holding

Indian Promoters % 73.8 66.9 110.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 33.1 4.7%  
FIIs % 7.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 0.0 -  
Shareholders   20,968 68,381 30.7%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS